We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Status of patients cancers during cancer trials let alone anything else. Obviously drugs that target HER2 positive cancers need to be given to people with HER2 positive cancer! Then the cancer's status needs to bo monitored during treatment to see if it's status changes to for example HER2 negative, in which case the treatment could be changed.
Two possibilities just from Astrazeneca in just the last few days!!!!!!!!!!!!!:-
https://www.lse.co.uk/rns/AZN/fda-accepts-dato-dxd-bla-for-breast-cancer-6gb18korpqpp8bb.html
https://www.lse.co.uk/rns/AZN/enhertu-approved-in-us-for-her2-solid-tumours-d992ucbs0xpl3ik.html
All IMHO.
TGTW, how many times must I tell you this. Parsortix can by used to clinically test any cancer when the test is developed and undertaken by a CLIA laboratory - no need for FDA approval. This is how the prostate test will be delivered for example. Also parsortix can be used to support clinical trials of any drug in any cancer type. The Angle labs are ALREADY doing this.
Read slowly and let it sink in.
FACT!
Without FDA apprival to test most cancers why would labs waste time and money investing in a testng machine that's not fully FDA approved!
Https://accessgudid.nlm.nih.gov/devices/search?query=parsortix
Better website with same info
- So gained 26.67% over Mon and Tues.
Now down 11.1%.
26.67 - 11.1 = Up 15.57%. Should not complain!
Https://fda.report/Company/Angle-P-L-C
is this new info? Seems like product specific filing rather than over all?
ANGLE plc
LON: AGL
OverviewFinancialsCompare
13.75 GBX −2.00 (12.70%)today
Should have gone to Specsavers big discounted sale on!
I did warn you same as January!
Perhaps they could mention in that conference that they have seen what has been happening elsewhere recently, and will not allow their small shareholders to be treated in such a fashion, in the event they ever look to move away from AIM?
Perhaps assurances of premium cash offers for those who cannot follow a de-listed entity, or something similar?
Not going to hold my breath. Anyway GLA.
Another snippet from the original RNS:-
"It is recognised that breast cancer can be highly heterogeneous and that HER2 status can change over time. In addition, results from a recent high impact study have revealed that patients categorised with HER2-low breast cancer (and defined as immunohistochemistry (IHC) score 1+ and 2+ and HER2-negative by FISH), can in fact, benefit from new HER2 targeted antibody-drug conjugates, where typical HER2 targeted drugs have previously been reserved for HER2-positive (HER2 IHC 3+ and/or HER2 FISH positive) breast cancer patients. This new understanding is driving the adoption of HER2-low targeted drugs such as ENHERTU(R) marketed by Daiichi-Sankyo and *****AstraZeneca*****.
This changing market dynamic has provided ANGLE and BioView with a major commercial opportunity to develop a quantitative CTC-based HER2 assay, to assess HER2 protein expression and/or gene amplification levels by analysing fluorescence intensities. This would be the only product-based solution on the market for this purpose ****leveraging both companies' previous FDA product clearances*****. Unlike current standard of care tests developed for use on FFPE tissue, a CTC HER2 assay could be used for longitudinal monitoring of HER2 status throughout disease progression, thereby ensuring the patient is targeted for the most appropriate treatment at every stage. ".
Hopefully some feedback from the conference will be positive and new investors buy into the future
I'm not a believer of the US players in the afternoon, they could just buy at any time.
I cannot believe people would sell 3p lower than the highs earlier, probably creep up later, I cannot see there being more selling than buying at the 14p level when it was 16.5-17p high earlier
For quantitative HER2 analysis based on CTCs, ANGLE and BioView have agreed to allow for the inclusion of third parties in this project and its funding as we move into the commercialisation stage after the initial development work is complete. The parties are continuing to discuss strategic routes to market with potential corporate partners. ".
The RNS on Monday basically confirmed the "initial development work is complete.".
So Angle and Bioview are open to another partner joining them.
I think this further explains the sp rise on Monday and Tuesday.
Clearly the market thinks this partnership could pay massive dividends.
If ANY Company in the World does a deal with Angle and Bioview it will be transformational for them both IMHO.
All IMHO.
Now only 11% down !
It will be interesting to see what happens after about 1pm when the USA players get involved. Yesterday the sp took off.
I think he's long gone from Agl now, these traders never hold more than a few trading hours. I still cannot get over it's back at 14p bid, thought it would be racing through 17p. Just shows you this market is awash with nervous wreck traders.
In fact give it 2 hrs?
My pleasure! FWIW, I hope it does not happen here.
I am not impressed with what those other outfits seem to be doing...the excuses they seem to be using, while not entirely without some merit, are IMO somewhat masking a variety of other, often self-inflicted issues, not to mention what seems to be a clear disregard for fiduciary duty that is meant to apply to all shareholders, not just a chosen few.
You could forgive those who might come to the conclusion that, after financially supporting company X for years and all the risk and opportunity cost of taking such a decision....when one such company finally gets to the stage of being in a position to reward those supporters...rug pull for all but a very few at the top table.
Ultimately, I think AIM directors - and those within this particular space especially - really should look a little closer in the mirror when it comes to why they are finding it so difficult to continually raise large amounts of cash.
Just a few thoughts and opinions, which you are all free to disagree with :) GLA.
LWHL.
Thank you for your input.
In the examples of C4 and ETX (and those other ones of late too), you are not going to be able to hold shares in an ISA once they de-list, so no, I mean sellers.
To be clear, I am not suggesting that this company is going to follow suit - I have absolutely no idea - but that theory might explain the 'jittery' sellers.
Honestly - why do I you get excited about this.
It’s just ramping and selling out.
We’ve all seen it here many, many times.
Spike. Drop. End of story.
Hats off to the mm's they shook it and the traders all panicked. Now it's hard to buy again. When it was 14-15p it was 14.66p bid online so once again they make a killing while many pi's lose more money buying high and selling low without giving their trades a chance
LWHL.
Don't you mean buyers?
Perhaps the sellers are ISA holders who have seen what has been happening in this space recently?
Just a thought....